The U.S. Food and Drug Administration has approved the first biosimilar to pegfilgrastim (Neulasta, Amgen), a granulocyte colony-stimulating factor used to reduce infection risk in patients with ...
Neulasta (pegfilgrastim) is a prescription drug used to prevent infection from certain cancer therapy and to treat radiation sickness. Neulasta’s cost may depend on factors such as your dosage and the ...
ZURICH, Nov 18 (Reuters) - The U.S. Food and Drug Administration has accepted Novartis unit Sandoz's submission for approval of a biosimilar version of U.S.-based Amgen's Neulasta drug that fights ...
The drug decreases the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs. Nilesh Gupta, MD, Lupin, ...
Lupin Limited announced on December 1 that it received FDA approval for its biosimilar product, ARMLUPEG (pegfilgrastim-unne). ARMLUPEG is approved as a 6 mg/0.6 mL single-dose prefilled syringe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results